GHRH Analog (Trans-3-hexenoic acid)
Tesamorelin
Stabilized GHRH analog studied for GH secretion, visceral adipose reduction, and IGF-1 elevation in preclinical and clinical research models.
Select Size
Tested by: Eurofins Scientific · Batch: VRC-TES-2406 · Jun 2026
About Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) stabilized with a trans-3-hexenoic acid modification that extends its half-life relative to native GHRH. It stimulates pulsatile GH secretion from the anterior pituitary and has been studied for its effects on IGF-1 elevation and visceral adipose tissue reduction. An FDA-approved form (Egrifta) is used for HIV-associated lipodystrophy, making it a well-characterized research tool in GH axis and metabolic studies.
Research Areas
Technical Specifications
Molecular Weight
5135.88 g/mol
Amino Acid Sequence
Trans-3-hexenoic acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂
Storage
Lyophilized: −20°C, stable 24 months. Reconstituted: 4°C, use within 28 days.
Solubility
Soluble in sterile water at ≥1 mg/mL
For Research Purposes Only. Tesamorelin is sold exclusively for in vitro laboratory research. Not for human consumption, diagnostic, therapeutic, or veterinary use. See our Research Use Disclaimer.